CA2795513A1 - Modulators of the gpr119 receptor and the treatment of disorders related thereto - Google Patents

Info

Publication number

CA2795513A1

CA2795513A1 CA2795513A CA2795513A CA2795513A1 CA 2795513 A1 CA2795513 A1 CA 2795513A1 CA 2795513 A CA2795513 A CA 2795513A CA 2795513 A CA2795513 A CA 2795513A CA 2795513 A1 CA2795513 A1 CA 2795513A1

Authority

CA

Canada

Prior art keywords

group

cyclohexyloxy

methylsulfonyl

alkyl

yloxy

Prior art date

2010-04-06

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 146
• 238000011282 treatment Methods 0.000 title claims abstract description 32
• 208000035475 disorder Diseases 0.000 title description 82
• 150000001875 compounds Chemical class 0.000 claims abstract description 331
• 150000003839 salts Chemical class 0.000 claims abstract description 111
• 239000012453 solvate Substances 0.000 claims abstract description 108
• 150000004677 hydrates Chemical class 0.000 claims abstract description 101
• 208000008589 Obesity Diseases 0.000 claims abstract description 46
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 46
• 235000020824 obesity Nutrition 0.000 claims abstract description 45
• 210000004369 blood Anatomy 0.000 claims abstract description 39
• 239000008280 blood Substances 0.000 claims abstract description 39
• 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract description 35
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims abstract description 35
• 239000003112 inhibitor Substances 0.000 claims abstract description 35
• 239000000859 incretin Substances 0.000 claims abstract description 34
• MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims abstract description 32
• 230000002503 metabolic effect Effects 0.000 claims abstract description 25
• 229940123208 Biguanide Drugs 0.000 claims abstract description 24
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims abstract description 22
• 239000003888 alpha glucosidase inhibitor Substances 0.000 claims abstract description 22
• 230000001668 ameliorated effect Effects 0.000 claims abstract description 21
• XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims abstract description 19
• 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims abstract description 18
• -1 C1-haloalkyl Chemical group 0.000 claims description 1008
• 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims description 246
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 193
• 229910052739 hydrogen Inorganic materials 0.000 claims description 154
• 125000001424 substituent group Chemical group 0.000 claims description 150
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 146
• 239000008177 pharmaceutical agent Substances 0.000 claims description 127
• 125000000623 heterocyclic group Chemical group 0.000 claims description 126
• 229910052736 halogen Inorganic materials 0.000 claims description 114
• 150000002367 halogens Chemical class 0.000 claims description 114
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 108
• 125000001072 heteroaryl group Chemical group 0.000 claims description 106
• 239000000203 mixture Substances 0.000 claims description 91
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 88
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 80
• DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims description 74
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 70
• 238000000034 method Methods 0.000 claims description 70
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 59
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 58
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 52
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 52
• 239000000825 pharmaceutical preparation Substances 0.000 claims description 48
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 47
• 229940127557 pharmaceutical product Drugs 0.000 claims description 47
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
• 238000002360 preparation method Methods 0.000 claims description 42
• 125000001188 haloalkyl group Chemical group 0.000 claims description 39
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 39
• 239000008194 pharmaceutical composition Substances 0.000 claims description 39
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 34
• 125000001153 fluoro group Chemical group F* 0.000 claims description 33
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 32
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 31
• 229910052757 nitrogen Inorganic materials 0.000 claims description 31
• 239000002552 dosage form Substances 0.000 claims description 29
• 210000000988 bone and bone Anatomy 0.000 claims description 27
• 238000009472 formulation Methods 0.000 claims description 26
• 239000003937 drug carrier Substances 0.000 claims description 25
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 24
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 23
• 125000004076 pyridyl group Chemical group 0.000 claims description 23
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 22
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 22
• 125000002098 pyridazinyl group Chemical group 0.000 claims description 22
• 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims description 21
• 239000003814 drug Substances 0.000 claims description 21
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 20
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 20
• 238000004519 manufacturing process Methods 0.000 claims description 20
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 20
• SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 19
• 241001465754 Metazoa Species 0.000 claims description 19
• 208000012902 Nervous system disease Diseases 0.000 claims description 19
• 229940100389 Sulfonylurea Drugs 0.000 claims description 19
• 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 claims description 19
• 229950004994 meglitinide Drugs 0.000 claims description 19
• 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 18
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 17
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
• 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims description 16
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 16
• 229910052799 carbon Inorganic materials 0.000 claims description 16
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 16
• YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 16
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 14
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 14
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 14
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 14
• 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 13
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 13
• 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 claims description 13
• 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 claims description 13
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 12
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
• 238000002560 therapeutic procedure Methods 0.000 claims description 11
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 10
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
• 125000006678 phenoxycarbonyl group Chemical group 0.000 claims description 10
• BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims description 9
• ZMLHBBXPXZXTSP-UHFFFAOYSA-N 2-fluoropropane Chemical group C[C](C)F ZMLHBBXPXZXTSP-UHFFFAOYSA-N 0.000 claims description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
• 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 7
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 7
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 5
• IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 5
• 150000004283 biguanides Chemical class 0.000 claims description 5
• XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims description 5
• 229960004111 buformin Drugs 0.000 claims description 5
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 5
• ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 5
• 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 4
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
• FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 4
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 4
• CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
• JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims description 3
• FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 3
• LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 3
• ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims description 3
• QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 3
• SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims description 3
• OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 claims description 2
• WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 claims description 2
• SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims description 2
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
• ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims description 2
• PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 claims 3
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims 3
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 2
• NVVSPGQEXMJZIR-BMIGLBTASA-N (1s,6r)-3-{[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]carbonyl}-6-(2,4,5-trifluorophenyl)cyclohex-3-en-1-amine Chemical compound C1([C@H]2CC=C(C[C@@H]2N)C(=O)N2CC=3N(C(=NN=3)C(F)(F)F)CC2)=CC(F)=C(F)C=C1F NVVSPGQEXMJZIR-BMIGLBTASA-N 0.000 claims 1
• QYRWMYNQCXSWLV-INIZCTEOSA-N (2s)-1-[2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethylamino]acetyl]pyrrolidine-2-carbonitrile Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCNCC(=O)N1CCC[C@H]1C#N QYRWMYNQCXSWLV-INIZCTEOSA-N 0.000 claims 1
• AEOKIJDXJROCJQ-KRWDZBQOSA-N (2s)-1-[2-[[2-methyl-4-(4-pyridin-3-ylimidazol-1-yl)butan-2-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(C)(C)CCN(C=1)C=NC=1C1=CC=CN=C1 AEOKIJDXJROCJQ-KRWDZBQOSA-N 0.000 claims 1
• 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
• UOCHFMVPMIYRHJ-QWRGUYRKSA-N 1-[(3s,4s)-4-amino-1-[4-(3,3-difluoropyrrolidin-1-yl)-1,3,5-triazin-2-yl]pyrrolidin-3-yl]-5,5-difluoropiperidin-2-one Chemical compound N1([C@H]2CN(C[C@@H]2N)C=2N=C(N=CN=2)N2CC(F)(F)CC2)CC(F)(F)CCC1=O UOCHFMVPMIYRHJ-QWRGUYRKSA-N 0.000 claims 1
• LNWWQYYLZVZXKS-UHFFFAOYSA-N 1-pyrrolidin-1-ylethanone Chemical compound CC(=O)N1CCCC1 LNWWQYYLZVZXKS-UHFFFAOYSA-N 0.000 claims 1
• NVSWJKWHLUTHLP-CPJSRVTESA-N 11-[(2s)-2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]propyl]-3-n,3-n,8-n,8-n-tetramethyl-11-(2h-tetrazol-5-yl)-5,6-dihydrodibenzo[1,3-a:1',3'-e][7]annulene-3,8-dicarboxamide Chemical compound C([C@H](C)NCC(=O)N1[C@@H](CCC1)C#N)C1(C2=CC=C(C=C2CCC2=CC(=CC=C21)C(=O)N(C)C)C(=O)N(C)C)C=1N=NNN=1 NVSWJKWHLUTHLP-CPJSRVTESA-N 0.000 claims 1
• FIMRNLAKAARHPD-IRXDYDNUSA-N 2-[4-[[2-[(2s,5r)-2-cyano-5-ethynylpyrrolidin-1-yl]-2-oxoethyl]amino]-4-methylpiperidin-1-yl]pyridine-4-carboxylic acid Chemical compound C1CC(C)(NCC(=O)N2[C@@H](CC[C@@H]2C#C)C#N)CCN1C1=CC(C(O)=O)=CC=N1 FIMRNLAKAARHPD-IRXDYDNUSA-N 0.000 claims 1
• XCTNLNITUUOHNO-JOCHJYFZSA-N 2-[[6-[(3r)-3-amino-3-methylpiperidin-1-yl]-1,3-dimethyl-2,4-dioxopyrrolo[3,2-d]pyrimidin-5-yl]methyl]-4-fluorobenzonitrile Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2C=C1N1CCC[C@@](C)(N)C1 XCTNLNITUUOHNO-JOCHJYFZSA-N 0.000 claims 1
• WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims 1
• OJPAHFRBKOJVTQ-CQSZACIVSA-N 6-[(3r)-3-aminopiperidin-1-yl]-5-[(2-chloro-5-fluorophenyl)methyl]-1,3-dimethylpyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C=1C(F)=CC=C(Cl)C=1CN1C=2C(=O)N(C)C(=O)N(C)C=2C=C1N1CCC[C@@H](N)C1 OJPAHFRBKOJVTQ-CQSZACIVSA-N 0.000 claims 1
• KNXWHBULIHZMAE-OALUTQOASA-N 8-[(3aS,6aS)-2,3,3a,5,6,6a-hexahydro-1H-pyrrolo[3,2-b]pyrrol-4-yl]-3-methyl-7-(3-methylbut-2-enyl)-1-phenacylpurine-2,6-dione Chemical compound N1([C@@H]2[C@H](CC1)NCC2)C2=NC=1N(C(N(C(C1N2CC=C(C)C)=O)CC(C2=CC=CC=C2)=O)=O)C KNXWHBULIHZMAE-OALUTQOASA-N 0.000 claims 1
• GUYMHFIHHOEFOA-ZCPGHIKRSA-N Carmegliptin Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@@H](CF)CC1=O GUYMHFIHHOEFOA-ZCPGHIKRSA-N 0.000 claims 1
• URRAHSMDPCMOTH-LNLFQRSKSA-N Denagliptin Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 claims 1
• DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 claims 1
• QLXKHBNJTPICNF-QMCAAQAGSA-N Sergliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=CC=CC=C1CC1=CC=C(OC)C=C1 QLXKHBNJTPICNF-QMCAAQAGSA-N 0.000 claims 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
• 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
• AKFNKZFJBFQFAA-DIOPXHOYSA-N ethyl 4-[[2-[(2s,4s)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]bicyclo[2.2.2]octane-1-carboxylate Chemical compound C1CC(C(=O)OCC)(CC2)CCC12NCC(=O)N1C[C@@H](F)C[C@H]1C#N AKFNKZFJBFQFAA-DIOPXHOYSA-N 0.000 claims 1
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
• QWEWGXUTRTXFRF-KBPBESRZSA-N gosogliptin Chemical compound C1C(F)(F)CCN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2N=CC=CN=2)C1 QWEWGXUTRTXFRF-KBPBESRZSA-N 0.000 claims 1
• UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 claims 1
• UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 claims 1
• WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 claims 1
• IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 abstract description 12
• 230000000694 effects Effects 0.000 description 49
• 206010012601 diabetes mellitus Diseases 0.000 description 39
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 37
• 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 description 35
• 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 description 35
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 34
• 239000000556 agonist Substances 0.000 description 30
• 239000000126 substance Substances 0.000 description 30
• 201000010099 disease Diseases 0.000 description 29
• 125000003545 alkoxy group Chemical group 0.000 description 27
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 23
• 239000008103 glucose Substances 0.000 description 22
• YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 21
• 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 description 21
• 150000001934 cyclohexanes Chemical class 0.000 description 21
• 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 description 20
• 108010088847 Peptide YY Proteins 0.000 description 20
• 102100029909 Peptide YY Human genes 0.000 description 20
• 102000011690 Adiponectin Human genes 0.000 description 19
• 108010076365 Adiponectin Proteins 0.000 description 19
• 108090000765 processed proteins & peptides Proteins 0.000 description 18
• 102000004877 Insulin Human genes 0.000 description 17
• 108090001061 Insulin Proteins 0.000 description 17
• 239000004480 active ingredient Substances 0.000 description 17
• 229940125396 insulin Drugs 0.000 description 17
• 239000000243 solution Substances 0.000 description 17
• 239000000843 powder Substances 0.000 description 16
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 15
• 102000005962 receptors Human genes 0.000 description 15
• 108020003175 receptors Proteins 0.000 description 15
• 230000037406 food intake Effects 0.000 description 14
• 230000004054 inflammatory process Effects 0.000 description 14
• 239000007788 liquid Substances 0.000 description 14
• 239000003826 tablet Substances 0.000 description 14
• 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 13
• 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 13
• 206010061218 Inflammation Diseases 0.000 description 13
• 241000699670 Mus sp. Species 0.000 description 13
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 13
• 210000004027 cell Anatomy 0.000 description 13
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 13
• 235000012631 food intake Nutrition 0.000 description 13
• 230000004224 protection Effects 0.000 description 13
• 208000011231 Crohn disease Diseases 0.000 description 12
• 239000002775 capsule Substances 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• 230000004044 response Effects 0.000 description 12
• 239000002904 solvent Substances 0.000 description 12
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 11
• 239000007787 solid Substances 0.000 description 11
• 239000000725 suspension Substances 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 229910001868 water Inorganic materials 0.000 description 11
• 210000001072 colon Anatomy 0.000 description 10
• 125000004438 haloalkoxy group Chemical group 0.000 description 10
• 102000004196 processed proteins & peptides Human genes 0.000 description 10
• 206010009900 Colitis ulcerative Diseases 0.000 description 9
• 201000006704 Ulcerative Colitis Diseases 0.000 description 9
• 230000007423 decrease Effects 0.000 description 9
• 201000001421 hyperglycemia Diseases 0.000 description 9
• 208000011580 syndromic disease Diseases 0.000 description 9
• 201000001320 Atherosclerosis Diseases 0.000 description 8
• 208000032928 Dyslipidaemia Diseases 0.000 description 8
• 206010020772 Hypertension Diseases 0.000 description 8
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
• 208000017170 Lipid metabolism disease Diseases 0.000 description 8
• 206010033307 Overweight Diseases 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 230000002093 peripheral effect Effects 0.000 description 8
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 7
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 7
• 206010022489 Insulin Resistance Diseases 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 125000003636 chemical group Chemical group 0.000 description 7
• 238000002648 combination therapy Methods 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 230000003914 insulin secretion Effects 0.000 description 7
• 230000003834 intracellular effect Effects 0.000 description 7
• 208000010125 myocardial infarction Diseases 0.000 description 7
• 230000028327 secretion Effects 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 230000037221 weight management Effects 0.000 description 7
• 208000001132 Osteoporosis Diseases 0.000 description 6
• 208000006011 Stroke Diseases 0.000 description 6
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 239000003472 antidiabetic agent Substances 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 208000029078 coronary artery disease Diseases 0.000 description 6
• 230000001771 impaired effect Effects 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 150000003254 radicals Chemical class 0.000 description 6
• 210000000664 rectum Anatomy 0.000 description 6
• 210000000813 small intestine Anatomy 0.000 description 6
• 239000000375 suspending agent Substances 0.000 description 6
• 238000001757 thermogravimetry curve Methods 0.000 description 6
• 230000002792 vascular Effects 0.000 description 6
• 238000013293 zucker diabetic fatty rat Methods 0.000 description 6
• UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 5
• 102100021198 Chemerin-like receptor 2 Human genes 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 101000750094 Homo sapiens Chemerin-like receptor 2 Proteins 0.000 description 5
• 208000031226 Hyperlipidaemia Diseases 0.000 description 5
• 208000001145 Metabolic Syndrome Diseases 0.000 description 5
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 5
• 230000009102 absorption Effects 0.000 description 5
• 238000010521 absorption reaction Methods 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 239000000443 aerosol Substances 0.000 description 5
• 239000002830 appetite depressant Substances 0.000 description 5
• 125000003118 aryl group Chemical group 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 230000004087 circulation Effects 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 235000005911 diet Nutrition 0.000 description 5
• 230000037213 diet Effects 0.000 description 5
• 239000002270 dispersing agent Substances 0.000 description 5
• 239000000839 emulsion Substances 0.000 description 5
• 230000014101 glucose homeostasis Effects 0.000 description 5
• 230000002641 glycemic effect Effects 0.000 description 5
• 125000005842 heteroatom Chemical group 0.000 description 5
• 208000006575 hypertriglyceridemia Diseases 0.000 description 5
• 238000001802 infusion Methods 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 238000001144 powder X-ray diffraction data Methods 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 239000007921 spray Substances 0.000 description 5
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 4
• GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 4
• 206010065687 Bone loss Diseases 0.000 description 4
• 208000024172 Cardiovascular disease Diseases 0.000 description 4
• RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 208000002705 Glucose Intolerance Diseases 0.000 description 4
• 229940123464 Thiazolidinedione Drugs 0.000 description 4
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 4
• 102100040247 Tumor necrosis factor Human genes 0.000 description 4
• 230000005856 abnormality Effects 0.000 description 4
• 229960002632 acarbose Drugs 0.000 description 4
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 4
• VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 4
• 229960001466 acetohexamide Drugs 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 230000033115 angiogenesis Effects 0.000 description 4
• 230000003178 anti-diabetic effect Effects 0.000 description 4
• 239000000883 anti-obesity agent Substances 0.000 description 4
• 229940125710 antiobesity agent Drugs 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 239000003086 colorant Substances 0.000 description 4
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 4
• 238000001938 differential scanning calorimetry curve Methods 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 235000019197 fats Nutrition 0.000 description 4
• 210000001035 gastrointestinal tract Anatomy 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 4
• 229940088597 hormone Drugs 0.000 description 4
• 239000005556 hormone Substances 0.000 description 4
• 210000003405 ileum Anatomy 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 210000000936 intestine Anatomy 0.000 description 4
• 239000007937 lozenge Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 229960003105 metformin Drugs 0.000 description 4
• 229960001110 miglitol Drugs 0.000 description 4
• 238000002156 mixing Methods 0.000 description 4
• 238000007410 oral glucose tolerance test Methods 0.000 description 4
• 230000011164 ossification Effects 0.000 description 4
• 229960003243 phenformin Drugs 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 125000006413 ring segment Chemical group 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 238000002411 thermogravimetry Methods 0.000 description 4
• 239000002562 thickening agent Substances 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 208000002177 Cataract Diseases 0.000 description 3
• 206010010904 Convulsion Diseases 0.000 description 3
• 229920002261 Corn starch Polymers 0.000 description 3
• 206010012735 Diarrhoea Diseases 0.000 description 3
• 229940100607 GPR119 agonist Drugs 0.000 description 3
• 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 3
• 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 3
• 108010010234 HDL Lipoproteins Proteins 0.000 description 3
• 102000015779 HDL Lipoproteins Human genes 0.000 description 3
• 206010019280 Heart failures Diseases 0.000 description 3
• 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 3
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 102000016267 Leptin Human genes 0.000 description 3
• 108010092277 Leptin Proteins 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 208000001164 Osteoporotic Fractures Diseases 0.000 description 3
• 206010036774 Proctitis Diseases 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 208000025865 Ulcer Diseases 0.000 description 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
• 238000007792 addition Methods 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 125000000217 alkyl group Chemical group 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 229940125709 anorectic agent Drugs 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• 229960001761 chlorpropamide Drugs 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229960004580 glibenclamide Drugs 0.000 description 3
• 229960004346 glimepiride Drugs 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
• 201000008980 hyperinsulinism Diseases 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 229940125425 inverse agonist Drugs 0.000 description 3
• 230000000302 ischemic effect Effects 0.000 description 3
• 208000017169 kidney disease Diseases 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 210000002429 large intestine Anatomy 0.000 description 3
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 208000015122 neurodegenerative disease Diseases 0.000 description 3
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
• 229960001243 orlistat Drugs 0.000 description 3
• 125000001715 oxadiazolyl group Chemical group 0.000 description 3
• 239000004031 partial agonist Substances 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 230000000291 postprandial effect Effects 0.000 description 3
• 238000000634 powder X-ray diffraction Methods 0.000 description 3
• 201000009104 prediabetes syndrome Diseases 0.000 description 3
• GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 229940044601 receptor agonist Drugs 0.000 description 3
• 239000000018 receptor agonist Substances 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 238000011808 rodent model Methods 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 229960002277 tolazamide Drugs 0.000 description 3
• 229960005371 tolbutamide Drugs 0.000 description 3
• 229960001729 voglibose Drugs 0.000 description 3
• 208000016261 weight loss Diseases 0.000 description 3
• 230000004580 weight loss Effects 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
• 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
• ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
• BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
• UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
• IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 208000010444 Acidosis Diseases 0.000 description 2
• 208000030090 Acute Disease Diseases 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 206010052895 Coronary artery insufficiency Diseases 0.000 description 2
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 description 2
• 208000004232 Enteritis Diseases 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• 206010017076 Fracture Diseases 0.000 description 2
• 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 2
• 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
• 206010020100 Hip fracture Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 206010027417 Metabolic acidosis Diseases 0.000 description 2
• 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
• 206010036783 Proctitis ulcerative Diseases 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 125000002252 acyl group Chemical group 0.000 description 2
• 210000000577 adipose tissue Anatomy 0.000 description 2
• 229960001667 alogliptin Drugs 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• 229940125708 antidiabetic agent Drugs 0.000 description 2
• 210000000436 anus Anatomy 0.000 description 2
• 235000019789 appetite Nutrition 0.000 description 2
• 230000036528 appetite Effects 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
• 229960002802 bromocriptine Drugs 0.000 description 2
• JMQJTNPKAFMQRR-UHFFFAOYSA-N butan-2-yl 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)CC)CCC1OC1CCC(OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 JMQJTNPKAFMQRR-UHFFFAOYSA-N 0.000 description 2
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 210000004534 cecum Anatomy 0.000 description 2
• 230000019522 cellular metabolic process Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• VKONPUDBRVKQLM-UHFFFAOYSA-N cyclohexane-1,4-diol Chemical compound OC1CCC(O)CC1 VKONPUDBRVKQLM-UHFFFAOYSA-N 0.000 description 2
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 229960003834 dapagliflozin Drugs 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 208000033679 diabetic kidney disease Diseases 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 238000007876 drug discovery Methods 0.000 description 2
• 210000001198 duodenum Anatomy 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 210000003158 enteroendocrine cell Anatomy 0.000 description 2
• 238000013213 extrapolation Methods 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 229940125753 fibrate Drugs 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 229960000346 gliclazide Drugs 0.000 description 2
• 229960001381 glipizide Drugs 0.000 description 2
• 230000004153 glucose metabolism Effects 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 230000005802 health problem Effects 0.000 description 2
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
• 230000003116 impacting effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
• 125000001041 indolyl group Chemical group 0.000 description 2
• 230000004968 inflammatory condition Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 239000004026 insulin derivative Substances 0.000 description 2
• 230000002473 insulinotropic effect Effects 0.000 description 2
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 229940039781 leptin Drugs 0.000 description 2
• 229960002397 linagliptin Drugs 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
• 210000003928 nasal cavity Anatomy 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 239000006201 parenteral dosage form Substances 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 2
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 229960002965 pravastatin Drugs 0.000 description 2
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000003449 preventive effect Effects 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• JVANLUCASVHWEW-UHFFFAOYSA-N pyridazine Chemical compound N1=C=C=C=C=N1 JVANLUCASVHWEW-UHFFFAOYSA-N 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
• 238000011552 rat model Methods 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000006722 reduction reaction Methods 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
• 229960000672 rosuvastatin Drugs 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 229960004937 saxagliptin Drugs 0.000 description 2
• 108010033693 saxagliptin Proteins 0.000 description 2
• 229940126842 sergliflozin Drugs 0.000 description 2
• HFLCZNNDZKKXCS-OUUBHVDSSA-N sergliflozin Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HFLCZNNDZKKXCS-OUUBHVDSSA-N 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
• 229960004425 sibutramine Drugs 0.000 description 2
• MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
• 229960004034 sitagliptin Drugs 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• LBVDJXAFBKDTID-UHFFFAOYSA-N tert-butyl 4-[4-(5-methylsulfonylpyridin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2N=CC(=CC=2)S(C)(=O)=O)CC1 LBVDJXAFBKDTID-UHFFFAOYSA-N 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 125000001113 thiadiazolyl group Chemical group 0.000 description 2
• 150000001467 thiazolidinediones Chemical class 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 125000004306 triazinyl group Chemical group 0.000 description 2
• 125000001425 triazolyl group Chemical group 0.000 description 2
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
• 229960001641 troglitazone Drugs 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 230000036269 ulceration Effects 0.000 description 2
• 229960001254 vildagliptin Drugs 0.000 description 2
• 235000019786 weight gain Nutrition 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• KCMHFFBYRZTIIA-UHFFFAOYSA-N (1,1,1-trifluoro-2-methylpropan-2-yl) 4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(S(C)(=O)=O)=CC=C1OC1CCC(OC2CCN(CC2)C(=O)OC(C)(C)C(F)(F)F)CC1 KCMHFFBYRZTIIA-UHFFFAOYSA-N 0.000 description 1
• VOOUUGXUJOWKLX-UHFFFAOYSA-N (2,2,3,3-tetrafluorocyclobutyl) 4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1=NC(S(=O)(=O)C)=CN=C1OC1CCC(OC2CCN(CC2)C(=O)OC2C(C(F)(F)C2)(F)F)CC1 VOOUUGXUJOWKLX-UHFFFAOYSA-N 0.000 description 1
• PMTLQIPNHPFWRD-UHFFFAOYSA-N (2-methylcyclopropyl)-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]methanone Chemical compound CC1CC1C(=O)N1CCC(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 PMTLQIPNHPFWRD-UHFFFAOYSA-N 0.000 description 1
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
• OJZDIGITASGCBW-UHFFFAOYSA-N (3-methoxyazetidin-1-yl)-[5-[4-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]oxycyclohexyl]oxypyrazin-2-yl]methanone Chemical compound C1C(OC)CN1C(=O)C(N=C1)=CN=C1OC1CCC(OC2CCN(CC2)C=2ON=C(N=2)C(C)C)CC1 OJZDIGITASGCBW-UHFFFAOYSA-N 0.000 description 1
• SYBVLGNXPNLLEH-UHFFFAOYSA-N (3-methyloxetan-3-yl)methyl 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CC(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CCN1C(=O)OCC1(C)COC1 SYBVLGNXPNLLEH-UHFFFAOYSA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• JTYMBPOYMGLPKA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 JTYMBPOYMGLPKA-UHFFFAOYSA-N 0.000 description 1
• UELPEIDTYUYPHA-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1=NC(S(=O)(=O)C)=CN=C1OC1CCC(OC2CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)CC1 UELPEIDTYUYPHA-UHFFFAOYSA-N 0.000 description 1
• HXJMVGYAJTXXJM-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-yl 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C(F)(F)F)CCC1OC1CCC(OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 HXJMVGYAJTXXJM-UHFFFAOYSA-N 0.000 description 1
• CRMDMXFYUNDUFA-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-yl 4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C(F)(F)F)CCC1OC1CCC(OC=2N=CC(=NC=2)S(C)(=O)=O)CC1 CRMDMXFYUNDUFA-UHFFFAOYSA-N 0.000 description 1
• 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• QHYYAJLNYXXUNY-UHFFFAOYSA-N 1,3-difluoropropan-2-yl 4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1=NC(S(=O)(=O)C)=CN=C1OC1CCC(OC2CCN(CC2)C(=O)OC(CF)CF)CC1 QHYYAJLNYXXUNY-UHFFFAOYSA-N 0.000 description 1
• FKEBGRGERFOBCE-UHFFFAOYSA-N 1-(4-chloro-2-fluorophenyl)-4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C=2C(=CC(Cl)=CC=2)F)CC1 FKEBGRGERFOBCE-UHFFFAOYSA-N 0.000 description 1
• WJBRLHRTMDDZNU-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C=2C=CC(F)=CC=2)CC1 WJBRLHRTMDDZNU-UHFFFAOYSA-N 0.000 description 1
• PRPPVWFVPPQADN-UHFFFAOYSA-N 1-(4-methoxyphenyl)-4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine Chemical compound C1=CC(OC)=CC=C1N1CCC(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 PRPPVWFVPPQADN-UHFFFAOYSA-N 0.000 description 1
• WZSHMVVIMOAEBX-UHFFFAOYSA-N 1-(4-methylphenyl)-4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine Chemical compound C1=CC(C)=CC=C1N1CCC(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 WZSHMVVIMOAEBX-UHFFFAOYSA-N 0.000 description 1
• GIBZNBFUFLJVBS-UHFFFAOYSA-N 1-cyclopropylsulfonyl-4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)S(=O)(=O)C2CC2)CC1 GIBZNBFUFLJVBS-UHFFFAOYSA-N 0.000 description 1
• XHHSPXXIRLGGBF-UHFFFAOYSA-N 1-fluoropropan-2-yl 4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(CF)C)CCC1OC1CCC(OC=2N=CC(=NC=2)S(C)(=O)=O)CC1 XHHSPXXIRLGGBF-UHFFFAOYSA-N 0.000 description 1
• GHMCHYHHSBMUAR-UHFFFAOYSA-N 1-hydroxypropan-2-yl 4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(CO)C)CCC1OC1CCC(OC=2N=CC(=NC=2)S(C)(=O)=O)CC1 GHMCHYHHSBMUAR-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• NTSQUYMGFWZWGZ-UHFFFAOYSA-N 2,2-difluoro-1-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)C(F)(F)CC)CCC1OC1CCC(OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 NTSQUYMGFWZWGZ-UHFFFAOYSA-N 0.000 description 1
• RRZKJFUOXRQZDN-UHFFFAOYSA-N 2,2-difluoro-1-[4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)C(F)(F)CC)CCC1OC1CCC(OC=2N=CC(=NC=2)S(C)(=O)=O)CC1 RRZKJFUOXRQZDN-UHFFFAOYSA-N 0.000 description 1
• WRVMDHRSVNXPGG-UHFFFAOYSA-N 2-(1-methylcyclopropyl)-4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylic acid Chemical compound C1C(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CCN(C(O)=O)C1C1(C)CC1 WRVMDHRSVNXPGG-UHFFFAOYSA-N 0.000 description 1
• 239000003315 2-(4-chlorophenoxy)-2-methylpropanoic acid Substances 0.000 description 1
• SGVQMKDQDTWFEM-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-(chloroamino)benzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=C(NCl)C=C1 SGVQMKDQDTWFEM-UHFFFAOYSA-N 0.000 description 1
• PTDAVJXWRGVQEW-UHFFFAOYSA-N 2-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]-5-(trifluoromethyl)pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C=2N=CC(=CC=2)C(F)(F)F)CC1 PTDAVJXWRGVQEW-UHFFFAOYSA-N 0.000 description 1
• ZWJLEEXZFZCXPE-UHFFFAOYSA-N 2-methyl-1-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]propan-1-one Chemical compound C1CN(C(=O)C(C)C)CCC1OC1CCC(OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 ZWJLEEXZFZCXPE-UHFFFAOYSA-N 0.000 description 1
• BLJVFYVTBPOEMW-UHFFFAOYSA-N 2-methyl-3-[4-[1-(5-methylpyridin-2-yl)piperidin-4-yl]oxycyclohexyl]oxy-6-methylsulfonylpyridine Chemical compound N1=CC(C)=CC=C1N1CCC(OC2CCC(CC2)OC=2C(=NC(=CC=2)S(C)(=O)=O)C)CC1 BLJVFYVTBPOEMW-UHFFFAOYSA-N 0.000 description 1
• FCEOWQRSFVQEOC-UHFFFAOYSA-N 2-methyl-5-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]pyrazine Chemical compound C1=NC(C)=CN=C1N1CCC(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 FCEOWQRSFVQEOC-UHFFFAOYSA-N 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• NUDONOCSYUVZOD-UHFFFAOYSA-N 2-methylpropyl 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC(C)C)CCC1OC1CCC(OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 NUDONOCSYUVZOD-UHFFFAOYSA-N 0.000 description 1
• SBJNIHDBQGTMPW-UHFFFAOYSA-N 2-methylsulfonyl-5-[4-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxycyclohexyl]oxypyrazine Chemical compound C1=NC(S(=O)(=O)C)=CN=C1OC1CCC(OC2CCN(CC(F)(F)F)CC2)CC1 SBJNIHDBQGTMPW-UHFFFAOYSA-N 0.000 description 1
• XNWMZBTZKRZRGD-UHFFFAOYSA-N 2-methylsulfonyl-5-[4-[1-(2,2,3,3-tetrafluoropropyl)piperidin-4-yl]oxycyclohexyl]oxypyrazine Chemical compound C1=NC(S(=O)(=O)C)=CN=C1OC1CCC(OC2CCN(CC(F)(F)C(F)F)CC2)CC1 XNWMZBTZKRZRGD-UHFFFAOYSA-N 0.000 description 1
• PKAKEFGIXRDJRP-UHFFFAOYSA-N 2-methylsulfonyl-5-[4-[1-[[1-(trifluoromethyl)cyclobutyl]methyl]piperidin-4-yl]oxycyclohexyl]oxypyrazine Chemical compound C1=NC(S(=O)(=O)C)=CN=C1OC1CCC(OC2CCN(CC3(CCC3)C(F)(F)F)CC2)CC1 PKAKEFGIXRDJRP-UHFFFAOYSA-N 0.000 description 1
• ANIDPORIGUTQGM-UHFFFAOYSA-N 2-methylsulfonyl-5-[4-[1-[[1-(trifluoromethyl)cyclopropyl]methyl]piperidin-4-yl]oxycyclohexyl]oxypyrazine Chemical compound C1=NC(S(=O)(=O)C)=CN=C1OC1CCC(OC2CCN(CC3(CC3)C(F)(F)F)CC2)CC1 ANIDPORIGUTQGM-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• YWYBFEVQNFKTFP-UHFFFAOYSA-N 3,3-dimethyl-1-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1OC1CCC(OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 YWYBFEVQNFKTFP-UHFFFAOYSA-N 0.000 description 1
• FIEKPUBASHBEKI-UHFFFAOYSA-N 3-(2-fluoropropan-2-yl)-5-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)(F)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)=N1 FIEKPUBASHBEKI-UHFFFAOYSA-N 0.000 description 1
• AJRWLKZUQOAIMM-UHFFFAOYSA-N 3-(2-fluoropropan-2-yl)-5-[4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)(F)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2N=CC(=NC=2)S(C)(=O)=O)=N1 AJRWLKZUQOAIMM-UHFFFAOYSA-N 0.000 description 1
• DUKFUUCTKNOESH-UHFFFAOYSA-N 3-(2-fluoropropan-2-yl)-5-[4-[4-(5-methylsulfonylpyridin-2-yl)oxycyclohexyl]oxypiperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)(F)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2N=CC(=CC=2)S(C)(=O)=O)=N1 DUKFUUCTKNOESH-UHFFFAOYSA-N 0.000 description 1
• UZROEFPXFJSNAL-UHFFFAOYSA-N 3-[4-[1-(5-ethylpyridin-2-yl)piperidin-4-yl]oxycyclohexyl]oxy-2-methyl-6-methylsulfonylpyridine Chemical compound N1=CC(CC)=CC=C1N1CCC(OC2CCC(CC2)OC=2C(=NC(=CC=2)S(C)(=O)=O)C)CC1 UZROEFPXFJSNAL-UHFFFAOYSA-N 0.000 description 1
• ISRTYVBWNUTNJX-UHFFFAOYSA-N 3-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound O1C(C(C)C)=NC(N2CCC(CC2)OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)=N1 ISRTYVBWNUTNJX-UHFFFAOYSA-N 0.000 description 1
• FWXOBUMEZGZCFP-UHFFFAOYSA-N 3-[4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidin-1-yl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound O1C(C(C)C)=NC(N2CCC(CC2)OC2CCC(CC2)OC=2N=CC(=NC=2)S(C)(=O)=O)=N1 FWXOBUMEZGZCFP-UHFFFAOYSA-N 0.000 description 1
• YHZHUSNVJPIZMU-UHFFFAOYSA-N 3-ethoxy-6-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]pyridazine Chemical compound N1=NC(OCC)=CC=C1N1CCC(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 YHZHUSNVJPIZMU-UHFFFAOYSA-N 0.000 description 1
• IBWYKAUAJJPTOS-UHFFFAOYSA-N 3-methyl-6-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]pyridazine Chemical compound N1=NC(C)=CC=C1N1CCC(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 IBWYKAUAJJPTOS-UHFFFAOYSA-N 0.000 description 1
• CTDDJAIENYOXBU-UHFFFAOYSA-N 3-propan-2-yl-5-[4-[4-[5-(1,2,4-triazol-1-yl)pyrazin-2-yl]oxycyclohexyl]oxypiperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2N=CC(=NC=2)N2N=CN=C2)=N1 CTDDJAIENYOXBU-UHFFFAOYSA-N 0.000 description 1
• DEIZUKMGLRBPHL-UHFFFAOYSA-N 3-tert-butyl-5-[4-[4-(2-fluoro-4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 DEIZUKMGLRBPHL-UHFFFAOYSA-N 0.000 description 1
• RVRMLICCNMPMKR-UHFFFAOYSA-N 3-tert-butyl-5-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)=N1 RVRMLICCNMPMKR-UHFFFAOYSA-N 0.000 description 1
• GOBKYRRHXHKJSD-UHFFFAOYSA-N 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxy-1-[3-(trifluoromethyl)phenyl]piperidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)CC1 GOBKYRRHXHKJSD-UHFFFAOYSA-N 0.000 description 1
• RHPBYOXAARSAMK-UHFFFAOYSA-N 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxy-1-[4-(trifluoromethoxy)phenyl]piperidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C=2C=CC(OC(F)(F)F)=CC=2)CC1 RHPBYOXAARSAMK-UHFFFAOYSA-N 0.000 description 1
• STATYCVKLHYWCY-UHFFFAOYSA-N 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxy-1-[4-(trifluoromethyl)phenyl]piperidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C=2C=CC(=CC=2)C(F)(F)F)CC1 STATYCVKLHYWCY-UHFFFAOYSA-N 0.000 description 1
• JDIJVAVQMKSBGO-UHFFFAOYSA-N 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxy-1-propan-2-ylsulfonylpiperidine Chemical compound C1CN(S(=O)(=O)C(C)C)CCC1OC1CCC(OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 JDIJVAVQMKSBGO-UHFFFAOYSA-N 0.000 description 1
• SXNFZIIQOGYPJD-UHFFFAOYSA-N 5-(2-fluoropropan-2-yl)-3-[4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidin-1-yl]-1,2,4-oxadiazole Chemical compound O1C(C(C)(F)C)=NC(N2CCC(CC2)OC2CCC(CC2)OC=2N=CC(=NC=2)S(C)(=O)=O)=N1 SXNFZIIQOGYPJD-UHFFFAOYSA-N 0.000 description 1
• AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 description 1
• ZGHIVANNODPRFE-UHFFFAOYSA-N 5-[4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2C(=NC(=CC=2)S(C)(=O)=O)C)=N1 ZGHIVANNODPRFE-UHFFFAOYSA-N 0.000 description 1
• FCGLHFVRUQZYNL-UHFFFAOYSA-N 5-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)=N1 FCGLHFVRUQZYNL-UHFFFAOYSA-N 0.000 description 1
• HXOYWRCNPOAECJ-UHFFFAOYSA-N 5-[4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidin-1-yl]-3-prop-1-en-2-yl-1,2,4-oxadiazole Chemical compound CC(=C)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2N=CC(=NC=2)S(C)(=O)=O)=N1 HXOYWRCNPOAECJ-UHFFFAOYSA-N 0.000 description 1
• CSOGRCIYURGVDY-UHFFFAOYSA-N 5-[4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2N=CC(=NC=2)S(C)(=O)=O)=N1 CSOGRCIYURGVDY-UHFFFAOYSA-N 0.000 description 1
• NWZKUJMSYXYFCY-UHFFFAOYSA-N 5-[[4-[4-(2-fluoro-4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]methyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(CN2CCC(CC2)OC2CCC(CC2)OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 NWZKUJMSYXYFCY-UHFFFAOYSA-N 0.000 description 1
• XTOCHTDNHREPJR-UHFFFAOYSA-N 5-[[4-[4-(5-methylsulfonylpyridin-2-yl)oxycyclohexyl]oxypiperidin-1-yl]methyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(CN2CCC(CC2)OC2CCC(CC2)OC=2N=CC(=CC=2)S(C)(=O)=O)=N1 XTOCHTDNHREPJR-UHFFFAOYSA-N 0.000 description 1
• DEFXTCVAVWSVDR-UHFFFAOYSA-N 5-chloro-2-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C=2N=CC(Cl)=CC=2)CC1 DEFXTCVAVWSVDR-UHFFFAOYSA-N 0.000 description 1
• WHCGQQXLXROWDU-UHFFFAOYSA-N 5-chloro-2-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]pyrimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C=2N=CC(Cl)=CN=2)CC1 WHCGQQXLXROWDU-UHFFFAOYSA-N 0.000 description 1
• AIOWAFLUHHLJDW-UHFFFAOYSA-N 5-ethyl-2-[4-[4-(2-fluoro-4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]pyrimidine Chemical compound N1=CC(CC)=CN=C1N1CCC(OC2CCC(CC2)OC=2C(=CC(=CC=2)S(C)(=O)=O)F)CC1 AIOWAFLUHHLJDW-UHFFFAOYSA-N 0.000 description 1
• PUPMYMPGLIJLQG-UHFFFAOYSA-N 5-ethyl-2-[4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidin-1-yl]pyrimidine Chemical compound N1=CC(CC)=CN=C1N1CCC(OC2CCC(CC2)OC=2C(=NC(=CC=2)S(C)(=O)=O)C)CC1 PUPMYMPGLIJLQG-UHFFFAOYSA-N 0.000 description 1
• VHMWEDOYMKTVDH-UHFFFAOYSA-N 5-ethyl-2-[4-[4-(5-methylsulfonylpyridin-2-yl)oxycyclohexyl]oxypiperidin-1-yl]pyrimidine Chemical compound N1=CC(CC)=CN=C1N1CCC(OC2CCC(CC2)OC=2N=CC(=CC=2)S(C)(=O)=O)CC1 VHMWEDOYMKTVDH-UHFFFAOYSA-N 0.000 description 1
• AXNKBQPQPNYXCJ-UHFFFAOYSA-N 5-fluoro-2-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C=2N=CC(F)=CC=2)CC1 AXNKBQPQPNYXCJ-UHFFFAOYSA-N 0.000 description 1
• ZEKBXRKPETUQAA-UHFFFAOYSA-N 5-methoxy-2-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]pyrimidine Chemical compound N1=CC(OC)=CN=C1N1CCC(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 ZEKBXRKPETUQAA-UHFFFAOYSA-N 0.000 description 1
• BVBBNXPGGKEKEV-UHFFFAOYSA-N 5-methyl-2-[4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidin-1-yl]pyrimidine Chemical compound N1=CC(C)=CN=C1N1CCC(OC2CCC(CC2)OC=2C(=NC(=CC=2)S(C)(=O)=O)C)CC1 BVBBNXPGGKEKEV-UHFFFAOYSA-N 0.000 description 1
• NXVRMOOFGPZWJS-UHFFFAOYSA-N 5-methyl-2-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]pyrimidine Chemical compound N1=CC(C)=CN=C1N1CCC(OC2CCC(CC2)OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 NXVRMOOFGPZWJS-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
• 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
• 208000011732 Abnormal glucose homeostasis Diseases 0.000 description 1
• 102000014777 Adipokines Human genes 0.000 description 1
• 108010078606 Adipokines Proteins 0.000 description 1
• 102000054930 Agouti-Related Human genes 0.000 description 1
• 101710127426 Agouti-related protein Proteins 0.000 description 1
• FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 101710095342 Apolipoprotein B Proteins 0.000 description 1
• 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
• 102000018616 Apolipoproteins B Human genes 0.000 description 1
• 108010027006 Apolipoproteins B Proteins 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• 208000029862 Barrett adenocarcinoma Diseases 0.000 description 1
• XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
• 229920002911 Colestipol Polymers 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000014997 Crohn colitis Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 208000013600 Diabetic vascular disease Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 102000015689 E-Selectin Human genes 0.000 description 1
• 108010024212 E-Selectin Proteins 0.000 description 1
• 206010014486 Elevated triglycerides Diseases 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 108010061435 Enalapril Proteins 0.000 description 1
• 108010066671 Enalaprilat Proteins 0.000 description 1
• 206010048554 Endothelial dysfunction Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 208000010228 Erectile Dysfunction Diseases 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
• 108010011459 Exenatide Proteins 0.000 description 1
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
• 206010016997 Forearm fracture Diseases 0.000 description 1
• 102400001370 Galanin Human genes 0.000 description 1
• 101800002068 Galanin Proteins 0.000 description 1
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
• 208000036391 Genetic obesity Diseases 0.000 description 1
• 108010016122 Ghrelin Receptors Proteins 0.000 description 1
• 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• 108050002557 Glucose-dependent insulinotropic receptors Proteins 0.000 description 1
• 206010018473 Glycosuria Diseases 0.000 description 1
• 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 1
• 101000928179 Homo sapiens Agouti-related protein Proteins 0.000 description 1
• 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 238000004566 IR spectroscopy Methods 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 206010022562 Intermittent claudication Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
• 208000007976 Ketosis Diseases 0.000 description 1
• 238000008214 LDL Cholesterol Methods 0.000 description 1
• 235000019687 Lamb Nutrition 0.000 description 1
• 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
• 102100031775 Leptin receptor Human genes 0.000 description 1
• 229940127470 Lipase Inhibitors Drugs 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
• 108010019598 Liraglutide Proteins 0.000 description 1
• 108010007859 Lisinopril Proteins 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 241000502522 Luscinia megarhynchos Species 0.000 description 1
• 108010000410 MSH receptor Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
• 102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
• 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
• 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
• 101710151321 Melanostatin Proteins 0.000 description 1
• 208000029725 Metabolic bone disease Diseases 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• 208000026072 Motor neurone disease Diseases 0.000 description 1
• 101100069093 Mus musculus Gpr119 gene Proteins 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
• 125000000815 N-oxide group Chemical group 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 102000030937 Neuromedin U receptor Human genes 0.000 description 1
• 108010002741 Neuromedin U receptor Proteins 0.000 description 1
• 102400000064 Neuropeptide Y Human genes 0.000 description 1
• 108090000189 Neuropeptides Proteins 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
• 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 229940123730 Orexin receptor antagonist Drugs 0.000 description 1
• 241000906034 Orthops Species 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 208000003076 Osteolysis Diseases 0.000 description 1
• 206010049088 Osteopenia Diseases 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229940122985 Peptide agonist Drugs 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 206010036618 Premenstrual syndrome Diseases 0.000 description 1
• 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000014675 Prion-associated disease Diseases 0.000 description 1
• 102000035554 Proglucagon Human genes 0.000 description 1
• 108010058003 Proglucagon Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 208000036379 Sigmoiditis Diseases 0.000 description 1
• JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 239000000150 Sympathomimetic Substances 0.000 description 1
• 206010071436 Systolic dysfunction Diseases 0.000 description 1
• 208000037063 Thinness Diseases 0.000 description 1
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 108010059705 Urocortins Proteins 0.000 description 1
• 102000005630 Urocortins Human genes 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• KUJMMMNGUYWDSA-KLAILNCOSA-N [(2r)-1,1,1-trifluoropropan-2-yl] 4-[4-(2-methyl-6-methylsulfonyl-1-oxidopyridin-1-ium-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)O[C@H](C)C(F)(F)F)CCC1OC1CCC(OC=2C(=[N+]([O-])C(=CC=2)S(C)(=O)=O)C)CC1 KUJMMMNGUYWDSA-KLAILNCOSA-N 0.000 description 1
• AYRCNGVHINWCKG-KLAILNCOSA-N [(2r)-1,1,1-trifluoropropan-2-yl] 4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)O[C@H](C)C(F)(F)F)CCC1OC1CCC(OC=2C(=NC(=CC=2)S(C)(=O)=O)C)CC1 AYRCNGVHINWCKG-KLAILNCOSA-N 0.000 description 1
• QNIPKJLMFWJIPO-QQFBHYJXSA-N [(2r)-1,1,1-trifluoropropan-2-yl] 4-[4-(3-methyl-5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)O[C@H](C)C(F)(F)F)CCC1OC1CCC(OC=2C(=NC(=CN=2)S(C)(=O)=O)C)CC1 QNIPKJLMFWJIPO-QQFBHYJXSA-N 0.000 description 1
• DKVGXZLGOSITAW-QQFBHYJXSA-N [(2r)-1,1,1-trifluoropropan-2-yl] 4-[4-(5-ethylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1=NC(S(=O)(=O)CC)=CN=C1OC1CCC(OC2CCN(CC2)C(=O)O[C@H](C)C(F)(F)F)CC1 DKVGXZLGOSITAW-QQFBHYJXSA-N 0.000 description 1
• AYRCNGVHINWCKG-GTPINHCMSA-N [(2s)-1,1,1-trifluoropropan-2-yl] 4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)O[C@@H](C)C(F)(F)F)CCC1OC1CCC(OC=2C(=NC(=CC=2)S(C)(=O)=O)C)CC1 AYRCNGVHINWCKG-GTPINHCMSA-N 0.000 description 1
• IQNWPYKAQHVNDA-ZLPCBKJTSA-N [(2s)-1-hydroxypropan-2-yl] 4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)O[C@H](CO)C)CCC1OC1CCC(OC=2C(=NC(=CC=2)S(C)(=O)=O)C)CC1 IQNWPYKAQHVNDA-ZLPCBKJTSA-N 0.000 description 1
• BWSDLNVTYWNALJ-ANYOXOOPSA-N [(2s)-1-phenylmethoxypropan-2-yl] 4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C([C@H](C)OC(=O)N1CCC(CC1)OC1CCC(CC1)OC=1C(=NC(=CC=1)S(C)(=O)=O)C)OCC1=CC=CC=C1 BWSDLNVTYWNALJ-ANYOXOOPSA-N 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000000478 adipokine Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 230000010085 airway hyperresponsiveness Effects 0.000 description 1
• 229950007884 alacepril Drugs 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
• 208000037884 allergic airway inflammation Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 239000004411 aluminium Substances 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229940000806 amaryl Drugs 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
• 230000000489 anti-atherogenic effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000001262 anti-secretory effect Effects 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 210000002403 aortic endothelial cell Anatomy 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000013011 aqueous formulation Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 235000021311 artificial sweeteners Nutrition 0.000 description 1
• 230000000923 atherogenic effect Effects 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 210000003403 autonomic nervous system Anatomy 0.000 description 1
• 125000003725 azepanyl group Chemical group 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 229950009252 beclobrate Drugs 0.000 description 1
• YWQGBCXVCXMSLJ-UHFFFAOYSA-N beclobrate Chemical compound C1=CC(OC(C)(CC)C(=O)OCC)=CC=C1CC1=CC=C(Cl)C=C1 YWQGBCXVCXMSLJ-UHFFFAOYSA-N 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 229960004530 benazepril Drugs 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 229960000516 bezafibrate Drugs 0.000 description 1
• IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
• 229920000080 bile acid sequestrant Polymers 0.000 description 1
• 229940096699 bile acid sequestrants Drugs 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 229950004495 binifibrate Drugs 0.000 description 1
• BFYRHDVAEJIBON-UHFFFAOYSA-N binifibrate Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 BFYRHDVAEJIBON-UHFFFAOYSA-N 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000036983 biotransformation Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
• 230000037182 bone density Effects 0.000 description 1
• 230000018678 bone mineralization Effects 0.000 description 1
• 230000037118 bone strength Effects 0.000 description 1
• 230000008416 bone turnover Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 235000019577 caloric intake Nutrition 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
• 229960000830 captopril Drugs 0.000 description 1
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 150000001723 carbon free-radicals Chemical class 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000003293 cardioprotective effect Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
• 229960005110 cerivastatin Drugs 0.000 description 1
• 229950005749 ceronapril Drugs 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
• 229950009226 ciglitazone Drugs 0.000 description 1
• 229960005025 cilazapril Drugs 0.000 description 1
• HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
• 230000001886 ciliary effect Effects 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229950003072 clinofibrate Drugs 0.000 description 1
• 229960001214 clofibrate Drugs 0.000 description 1
• KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
• 229950008441 clofibric acid Drugs 0.000 description 1
• TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 229960002604 colestipol Drugs 0.000 description 1
• GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 229940096422 collagen type i Drugs 0.000 description 1
• 201000010897 colon adenocarcinoma Diseases 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• KHKUPRQZOHQPBH-UHFFFAOYSA-N cyclopentyl 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCC(OC2CCN(CC2)C(=O)OC2CCCC2)CC1 KHKUPRQZOHQPBH-UHFFFAOYSA-N 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
• 229960005227 delapril Drugs 0.000 description 1
• WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 229940089126 diabeta Drugs 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 125000005432 dialkylcarboxamide group Chemical group 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 238000000113 differential scanning calorimetry Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 230000003467 diminishing effect Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 230000002183 duodenal effect Effects 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 229910001651 emery Inorganic materials 0.000 description 1
• 229960000873 enalapril Drugs 0.000 description 1
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
• 229960002680 enalaprilat Drugs 0.000 description 1
• MZYVOFLIPYDBGD-MLZQUWKJSA-N enalaprilat dihydrate Chemical compound O.O.C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 MZYVOFLIPYDBGD-MLZQUWKJSA-N 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 230000008694 endothelial dysfunction Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 208000010227 enterocolitis Diseases 0.000 description 1
• 229960002179 ephedrine Drugs 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 229960003501 etofibrate Drugs 0.000 description 1
• XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
• 229950009036 etofylline clofibrate Drugs 0.000 description 1
• KYAKGJDISSNVPZ-UHFFFAOYSA-N etofylline clofibrate Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KYAKGJDISSNVPZ-UHFFFAOYSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 231100000318 excitotoxic Toxicity 0.000 description 1
• 230000003492 excitotoxic effect Effects 0.000 description 1
• 229960001519 exenatide Drugs 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 229960002297 fenofibrate Drugs 0.000 description 1
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 210000000497 foam cell Anatomy 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 210000000245 forearm Anatomy 0.000 description 1
• 229960002490 fosinopril Drugs 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000000446 fuel Substances 0.000 description 1
• 208000020694 gallbladder disease Diseases 0.000 description 1
• 230000030136 gastric emptying Effects 0.000 description 1
• 108010020107 gastric inhibitory polypeptide (3-42) Proteins 0.000 description 1
• 239000003349 gelling agent Substances 0.000 description 1
• 229960003627 gemfibrozil Drugs 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• BOVGTQGAOIONJV-UHFFFAOYSA-N gliclazide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CC2CCCC2C1 BOVGTQGAOIONJV-UHFFFAOYSA-N 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
• 230000035780 glucosuria Effects 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 229940120105 glynase Drugs 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 238000002017 high-resolution X-ray diffraction Methods 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 239000003667 hormone antagonist Substances 0.000 description 1
• 102000055839 human AGRP Human genes 0.000 description 1
• 102000056352 human GPR119 Human genes 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 208000009326 ileitis Diseases 0.000 description 1
• 229960001195 imidapril Drugs 0.000 description 1
• KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 201000006747 infectious mononucleosis Diseases 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 208000037493 inherited obesity Diseases 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 208000021156 intermittent vascular claudication Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• 230000004140 ketosis Effects 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 108010019813 leptin receptors Proteins 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 230000006372 lipid accumulation Effects 0.000 description 1
• 229960002701 liraglutide Drugs 0.000 description 1
• 229960002394 lisinopril Drugs 0.000 description 1
• CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
• 208000028755 loss of height Diseases 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000014380 magnesium carbonate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 229960000299 mazindol Drugs 0.000 description 1
• 235000012054 meals Nutrition 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 210000001767 medulla oblongata Anatomy 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
• 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229960003365 mitiglinide Drugs 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• QDGJRJXRCYMHKY-UHFFFAOYSA-N n,n-dimethyl-5-[4-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]oxycyclohexyl]oxypyrazine-2-carboxamide Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC2CCC(CC2)OC=2N=CC(=NC=2)C(=O)N(C)C)=N1 QDGJRJXRCYMHKY-UHFFFAOYSA-N 0.000 description 1
• DGBKNTVAKIFYNU-UHFFFAOYSA-N n-(2-fluoro-4-methylsulfonylphenyl)-5-nitro-6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidin-4-amine Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(NC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)N(=O)=O)=N1 DGBKNTVAKIFYNU-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 235000021096 natural sweeteners Nutrition 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 229940000041 nervous system drug Drugs 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 108010089579 neuropeptide Y2 receptor Proteins 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 229950005171 nicofibrate Drugs 0.000 description 1
• RARQHAFNGNPQCZ-UHFFFAOYSA-N nicofibrate Chemical compound C=1C=CN=CC=1COC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 RARQHAFNGNPQCZ-UHFFFAOYSA-N 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
• 230000002474 noradrenergic effect Effects 0.000 description 1
• 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
• 230000000474 nursing effect Effects 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 238000009806 oophorectomy Methods 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000001582 osteoblastic effect Effects 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 208000014965 pancolitis Diseases 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 108010070727 peptide YY receptor Proteins 0.000 description 1
• 230000002263 peptidergic effect Effects 0.000 description 1
• 229960002582 perindopril Drugs 0.000 description 1
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 239000003614 peroxisome proliferator Substances 0.000 description 1
• 229960003562 phentermine Drugs 0.000 description 1
• QXCOYYIBKPSJHY-UHFFFAOYSA-N phenyl 4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1=NC(S(=O)(=O)C)=CN=C1OC1CCC(OC2CCN(CC2)C(=O)OC=2C=CC=CC=2)CC1 QXCOYYIBKPSJHY-UHFFFAOYSA-N 0.000 description 1
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 229950000957 pirifibrate Drugs 0.000 description 1
• YJBIJSVYPHRVCI-UHFFFAOYSA-N pirifibrate Chemical compound C=1C=CC(CO)=NC=1COC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 YJBIJSVYPHRVCI-UHFFFAOYSA-N 0.000 description 1
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
• 229960002797 pitavastatin Drugs 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229940096058 prandin Drugs 0.000 description 1
• 229960002847 prasterone Drugs 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 229960005385 proguanil Drugs 0.000 description 1
• ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
• IFQVIHLMDKQYRO-UHFFFAOYSA-N propan-2-yl 4-[4-(2-fluoro-4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)CC1 IFQVIHLMDKQYRO-UHFFFAOYSA-N 0.000 description 1
• YKUPDOYJJSESIU-UHFFFAOYSA-N propan-2-yl 4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C(=NC(=CC=2)S(C)(=O)=O)C)CC1 YKUPDOYJJSESIU-UHFFFAOYSA-N 0.000 description 1
• WDHJLWYQXNKFNB-UHFFFAOYSA-N propan-2-yl 4-[4-(2-methyl-6-pyrimidin-5-ylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C(=NC(=CC=2)C=2C=NC=NC=2)C)CC1 WDHJLWYQXNKFNB-UHFFFAOYSA-N 0.000 description 1
• VXXLYISSPGWYIP-UHFFFAOYSA-N propan-2-yl 4-[4-(2-methylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C(=NC=CC=2)C)CC1 VXXLYISSPGWYIP-UHFFFAOYSA-N 0.000 description 1
• LNWHCWJXRQNAPW-UHFFFAOYSA-N propan-2-yl 4-[4-(3-methyl-5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C(=NC(=CN=2)S(C)(=O)=O)C)CC1 LNWHCWJXRQNAPW-UHFFFAOYSA-N 0.000 description 1
• QCTQXKOMSIAABV-UHFFFAOYSA-N propan-2-yl 4-[4-(4-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C(=CC(=NC=2)S(C)(=O)=O)C)CC1 QCTQXKOMSIAABV-UHFFFAOYSA-N 0.000 description 1
• LLGHXXPYWWHILE-UHFFFAOYSA-N propan-2-yl 4-[4-(5-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C=C(C)C(=NC=2)S(C)(=O)=O)CC1 LLGHXXPYWWHILE-UHFFFAOYSA-N 0.000 description 1
• OOZUGTUUVHOIQS-UHFFFAOYSA-N propan-2-yl 4-[4-(5-methylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2N=CC(=NC=2)S(C)(=O)=O)CC1 OOZUGTUUVHOIQS-UHFFFAOYSA-N 0.000 description 1
• NAKCCNLXMXEINQ-UHFFFAOYSA-N propan-2-yl 4-[4-(5-methylsulfonylpyridin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2N=CC(=CC=2)S(C)(=O)=O)CC1 NAKCCNLXMXEINQ-UHFFFAOYSA-N 0.000 description 1
• SMPSBFDLLRSWBD-UHFFFAOYSA-N propan-2-yl 4-[4-(5-pyridazin-4-ylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2N=CC(=NC=2)C=2C=NN=CC=2)CC1 SMPSBFDLLRSWBD-UHFFFAOYSA-N 0.000 description 1
• NNJSOLCYWRDVHG-UHFFFAOYSA-N propan-2-yl 4-[4-(6-bromo-2-methylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C(=NC(Br)=CC=2)C)CC1 NNJSOLCYWRDVHG-UHFFFAOYSA-N 0.000 description 1
• OOLNCJHOEKZASK-UHFFFAOYSA-N propan-2-yl 4-[4-(6-bromopyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C=NC(Br)=CC=2)CC1 OOLNCJHOEKZASK-UHFFFAOYSA-N 0.000 description 1
• LLJNAIXEMWXHQL-UHFFFAOYSA-N propan-2-yl 4-[4-(6-cyano-2-methylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C(=NC(=CC=2)C#N)C)CC1 LLJNAIXEMWXHQL-UHFFFAOYSA-N 0.000 description 1
• PEUNHFFUIQNSAW-UHFFFAOYSA-N propan-2-yl 4-[4-(6-cyclopropylsulfonyl-2-methylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C(=NC(=CC=2)S(=O)(=O)C2CC2)C)CC1 PEUNHFFUIQNSAW-UHFFFAOYSA-N 0.000 description 1
• HSIVFKVMEYGYQB-UHFFFAOYSA-N propan-2-yl 4-[4-(6-ethylsulfonyl-2-methylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(S(=O)(=O)CC)=CC=C1OC1CCC(OC2CCN(CC2)C(=O)OC(C)C)CC1 HSIVFKVMEYGYQB-UHFFFAOYSA-N 0.000 description 1
• CCJKJIRNMRHRGY-UHFFFAOYSA-N propan-2-yl 4-[4-(6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C=NC(=CC=2)S(C)(=O)=O)CC1 CCJKJIRNMRHRGY-UHFFFAOYSA-N 0.000 description 1
• GTVGMEAPHYIYRB-UHFFFAOYSA-N propan-2-yl 4-[4-[4-(3,3-difluoroazetidin-1-yl)sulfonylphenoxy]cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C=CC(=CC=2)S(=O)(=O)N2CC(F)(F)C2)CC1 GTVGMEAPHYIYRB-UHFFFAOYSA-N 0.000 description 1
• RUJFSUABTOVCOI-UBVWURDFSA-N propan-2-yl 4-[4-[4-[(2r)-2-amino-3-(3,3-difluoroazetidin-1-yl)-3-oxopropyl]phenoxy]cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C=CC(C[C@@H](N)C(=O)N3CC(F)(F)C3)=CC=2)CC1 RUJFSUABTOVCOI-UBVWURDFSA-N 0.000 description 1
• RUJFSUABTOVCOI-IWAAJCSBSA-N propan-2-yl 4-[4-[4-[(2s)-2-amino-3-(3,3-difluoroazetidin-1-yl)-3-oxopropyl]phenoxy]cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C=CC(C[C@H](N)C(=O)N3CC(F)(F)C3)=CC=2)CC1 RUJFSUABTOVCOI-IWAAJCSBSA-N 0.000 description 1
• YHZQHPIHORLXAE-UHFFFAOYSA-N propan-2-yl 4-[4-[5-(1,2,4-triazol-1-yl)pyrazin-2-yl]oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2N=CC(=NC=2)N2N=CN=C2)CC1 YHZQHPIHORLXAE-UHFFFAOYSA-N 0.000 description 1
• ZMNSGYAALDIJDZ-UHFFFAOYSA-N propan-2-yl 4-[4-[6-(1,2,4-triazol-1-yl)pyridin-3-yl]oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1CCC(OC=2C=NC(=CC=2)N2N=CN=C2)CC1 ZMNSGYAALDIJDZ-UHFFFAOYSA-N 0.000 description 1
• DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 239000011241 protective layer Substances 0.000 description 1
• 229940076372 protein antagonist Drugs 0.000 description 1
• 230000022558 protein metabolic process Effects 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
• 229960003908 pseudoephedrine Drugs 0.000 description 1
• 239000000719 purinergic P2Y receptor antagonist Substances 0.000 description 1
• 210000004915 pus Anatomy 0.000 description 1
• 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 229960001455 quinapril Drugs 0.000 description 1
• JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 229960002354 repaglinide Drugs 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 230000000250 revascularization Effects 0.000 description 1
• XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
• 229950010764 rivoglitazone Drugs 0.000 description 1
• 229960000804 ronifibrate Drugs 0.000 description 1
• AYJVGKWCGIYEAK-UHFFFAOYSA-N ronifibrate Chemical compound C=1C=CN=CC=1C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 AYJVGKWCGIYEAK-UHFFFAOYSA-N 0.000 description 1
• PESUBZXOIRAYCH-UHFFFAOYSA-N s-cyclopropyl 4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carbothioate Chemical compound CC1=NC(S(C)(=O)=O)=CC=C1OC1CCC(OC2CCN(CC2)C(=O)SC2CC2)CC1 PESUBZXOIRAYCH-UHFFFAOYSA-N 0.000 description 1
• KBHLTGAVPXOFQQ-UHFFFAOYSA-N s-propan-2-yl 4-[4-(2-methyl-6-methylsulfonylpyridin-3-yl)oxycyclohexyl]oxypiperidine-1-carbothioate Chemical compound C1CN(C(=O)SC(C)C)CCC1OC1CCC(OC=2C(=NC(=CC=2)S(C)(=O)=O)C)CC1 KBHLTGAVPXOFQQ-UHFFFAOYSA-N 0.000 description 1
• 230000036186 satiety Effects 0.000 description 1
• 235000019627 satiety Nutrition 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000000276 sedentary effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 210000001599 sigmoid colon Anatomy 0.000 description 1
• 229960004058 simfibrate Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 108091008012 small dense LDL Proteins 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 206010041569 spinal fracture Diseases 0.000 description 1
• 229960002909 spirapril Drugs 0.000 description 1
• HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
• 108700035424 spirapril Proteins 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 229940127230 sympathomimetic drug Drugs 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000002278 tabletting lubricant Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
• 229950007151 taspoglutide Drugs 0.000 description 1
• 108010048573 taspoglutide Proteins 0.000 description 1
• 229960004084 temocapril Drugs 0.000 description 1
• FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
• SVXWWBICSBHUSJ-UHFFFAOYSA-N tert-butyl 2-[4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidin-1-yl]acetate Chemical compound C1CN(CC(=O)OC(C)(C)C)CCC1OC1CCC(OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 SVXWWBICSBHUSJ-UHFFFAOYSA-N 0.000 description 1
• AHLXXFCNLCSIFA-UHFFFAOYSA-N tert-butyl 4-[4-(2-fluoro-4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)CC1 AHLXXFCNLCSIFA-UHFFFAOYSA-N 0.000 description 1
• YJURBCAKUXHXOT-UHFFFAOYSA-N tert-butyl 4-[4-(3-fluoro-4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2C=C(F)C(=CC=2)S(C)(=O)=O)CC1 YJURBCAKUXHXOT-UHFFFAOYSA-N 0.000 description 1
• XQORTTOFCIYWRP-UHFFFAOYSA-N tert-butyl 4-[4-(4-cyanophenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2C=CC(=CC=2)C#N)CC1 XQORTTOFCIYWRP-UHFFFAOYSA-N 0.000 description 1
• IHMXIXXXCQYFLP-UHFFFAOYSA-N tert-butyl 4-[4-(4-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2C=CC(=CC=2)S(C)(=O)=O)CC1 IHMXIXXXCQYFLP-UHFFFAOYSA-N 0.000 description 1
• XSZLOVGAJHENIK-UHFFFAOYSA-N tert-butyl 4-[4-(5-cyanopyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2N=CC(=NC=2)C#N)CC1 XSZLOVGAJHENIK-UHFFFAOYSA-N 0.000 description 1
• TUTKKOYFWDGWRX-UHFFFAOYSA-N tert-butyl 4-[4-(5-fluoro-2-methylsulfonylphenoxy)cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2C(=CC=C(F)C=2)S(C)(=O)=O)CC1 TUTKKOYFWDGWRX-UHFFFAOYSA-N 0.000 description 1
• NPLNRCPGFZKICQ-UHFFFAOYSA-N tert-butyl 4-[4-(5-propan-2-ylsulfonylpyrazin-2-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1=NC(S(=O)(=O)C(C)C)=CN=C1OC1CCC(OC2CCN(CC2)C(=O)OC(C)(C)C)CC1 NPLNRCPGFZKICQ-UHFFFAOYSA-N 0.000 description 1
• KNUUIBFTQJEJPJ-UHFFFAOYSA-N tert-butyl 4-[4-(6-bromopyridazin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2N=NC(Br)=CC=2)CC1 KNUUIBFTQJEJPJ-UHFFFAOYSA-N 0.000 description 1
• BZUSFWAKFVKNMZ-UHFFFAOYSA-N tert-butyl 4-[4-(6-methylsulfonylpyridazin-3-yl)oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2N=NC(=CC=2)S(C)(=O)=O)CC1 BZUSFWAKFVKNMZ-UHFFFAOYSA-N 0.000 description 1
• GFCQSWISGFWEGX-UHFFFAOYSA-N tert-butyl 4-[4-[4-(1,2,4-triazol-1-yl)phenoxy]cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2C=CC(=CC=2)N2N=CN=C2)CC1 GFCQSWISGFWEGX-UHFFFAOYSA-N 0.000 description 1
• KUZTUIQKVDJAFT-UHFFFAOYSA-N tert-butyl 4-[4-[4-(2-cyanoethyl)phenoxy]cyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2C=CC(CCC#N)=CC=2)CC1 KUZTUIQKVDJAFT-UHFFFAOYSA-N 0.000 description 1
• SAYRJSLPYXWFSC-UHFFFAOYSA-N tert-butyl 4-[4-[5-(1,2,4-triazol-1-yl)pyrazin-2-yl]oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1CCC(OC=2N=CC(=NC=2)N2N=CN=C2)CC1 SAYRJSLPYXWFSC-UHFFFAOYSA-N 0.000 description 1
• QGJZCNZLQJHOHH-UHFFFAOYSA-N tert-butyl 4-[4-[5-(dimethylcarbamoyl)-6-methylpyridin-2-yl]oxycyclohexyl]oxypiperidine-1-carboxylate Chemical compound N1=C(C)C(C(=O)N(C)C)=CC=C1OC1CCC(OC2CCN(CC2)C(=O)OC(C)(C)C)CC1 QGJZCNZLQJHOHH-UHFFFAOYSA-N 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 239000003749 thyromimetic agent Substances 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 229940035266 tolinase Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 229960002051 trandolapril Drugs 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 206010048828 underweight Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 239000000777 urocortin Substances 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 239000011345 viscous material Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1